UA110806C2 - Мікобактеріальна антигенна композиція - Google Patents

Мікобактеріальна антигенна композиція

Info

Publication number
UA110806C2
UA110806C2 UAA201306356A UAA201306356A UA110806C2 UA 110806 C2 UA110806 C2 UA 110806C2 UA A201306356 A UAA201306356 A UA A201306356A UA A201306356 A UAA201306356 A UA A201306356A UA 110806 C2 UA110806 C2 UA 110806C2
Authority
UA
Ukraine
Prior art keywords
immunogenic composition
mycobacterial
mycobacterial immunogenic
composition
medicine
Prior art date
Application number
UAA201306356A
Other languages
English (en)
Russian (ru)
Inventor
Стефан Андре Ґеорґес Ґодарт
Аміна Ланан
Домінік Інґрід Лемоін
Original Assignee
Ґлаксосмітклайн Байолоджікалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ґлаксосмітклайн Байолоджікалз С.А. filed Critical Ґлаксосмітклайн Байолоджікалз С.А.
Publication of UA110806C2 publication Critical patent/UA110806C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується імуногенної композиції, яка містить антиген, споріднений з Rv1196, де антиген, споріднений з Rv1196, включає (а) послідовність, що має принаймні 90 % ідентичності з послідовністю SEQ ID No: 1 або (b) фрагмент послідовності SEQ ID No: 1, який містить принаймні 350 амінокислот у довжину, та де електропровідність композиції складає 5 мСм/см або менше, а рН вказаної композиції лежить в інтервалі від 7,0, до 9,0.
UAA201306356A 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція UA110806C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072817 WO2012080370A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (1)

Publication Number Publication Date
UA110806C2 true UA110806C2 (uk) 2016-02-25

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201306356A UA110806C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція
UAA201306355A UA110118C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201306355A UA110118C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Country Status (32)

Country Link
US (5) US9352030B2 (uk)
EP (4) EP3593813A1 (uk)
JP (2) JP5951634B2 (uk)
KR (3) KR101951894B1 (uk)
CN (4) CN106822883A (uk)
AR (1) AR084285A1 (uk)
AU (2) AU2011343368C1 (uk)
BR (2) BR112013014598A2 (uk)
CA (2) CA2819298A1 (uk)
CO (2) CO6751288A2 (uk)
CY (1) CY1122187T1 (uk)
DK (3) DK2651437T3 (uk)
EA (2) EA027920B1 (uk)
ES (3) ES2748651T3 (uk)
HR (3) HRP20160362T1 (uk)
HU (3) HUE027932T2 (uk)
IL (2) IL226450A0 (uk)
LT (1) LT3023106T (uk)
ME (1) ME02380B (uk)
MX (2) MX344280B (uk)
MY (1) MY161412A (uk)
PL (3) PL2651437T3 (uk)
PT (2) PT2651436E (uk)
RS (1) RS54687B1 (uk)
SG (2) SG190937A1 (uk)
SI (3) SI2651436T1 (uk)
SM (1) SMT201600118B (uk)
TW (1) TW201305192A (uk)
UA (2) UA110806C2 (uk)
UY (1) UY33802A (uk)
WO (2) WO2012080370A1 (uk)
ZA (2) ZA201304015B (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
EP3593813A1 (en) * 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
LT2661253T (lt) * 2011-01-04 2017-05-25 Archivel Farma, Sl Liposomų kompozicija, tinkama tuberkuliozės gydymui arba prevencijai
IN2014MN01594A (uk) 2012-01-12 2015-05-08 Archivel Farma Sl
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
KR20220136455A (ko) 2014-04-23 2022-10-07 주노 쎄러퓨티크스 인코퍼레이티드 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
CA3045952A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
JP7291633B2 (ja) 2017-05-30 2023-06-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アジュバントを製造する方法
CA3083078A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
WO2020026147A1 (en) 2018-07-31 2020-02-06 Glaxosmithkline Biologicals Sa Antigen purification method
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
US20220235095A1 (en) 2019-06-05 2022-07-28 Glaxosmithkline Biologicals Sa Saponin purification
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4028051A1 (en) 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
CN114728051A (zh) 2019-11-22 2022-07-08 葛兰素史克生物有限公司 细菌糖糖缀合物疫苗的剂量和施用
EP4146378A1 (en) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Microfluidic mixing device and methods of use
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
US20240026407A1 (en) 2020-12-09 2024-01-25 Glaxosmithkline Biologicals Sa Modification of saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997009429A2 (en) 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
DE69637879D1 (de) 1995-09-01 2009-04-30 Corixa Corp Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
ES2216280T3 (es) * 1997-04-08 2004-10-16 MERCK & CO., INC. Formulaciones estabilizadas de papilomavirus humano.
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
CN1163602C (zh) * 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
SI1542732T1 (sl) 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fuzijski proteini Mycobacterium tuberculosis
AP1695A (en) 2000-06-29 2006-12-17 Glaxosmithkline Biologicals Sa Multivalent vaccine composition.
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
ATE543832T1 (de) 2005-04-29 2012-02-15 Glaxosmithkline Biolog Sa Verfahren zur vorbeugung oder behandlung einer m.-tuberculosis-infektion
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
KR20110091817A (ko) 2007-05-24 2011-08-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
US8420081B2 (en) 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
WO2009111874A1 (en) 2008-03-11 2009-09-17 The Royal Institution For The Advancement Of Learning/ Mcgiil University Low-temperature wafer level processing for mems devices
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
EP3593813A1 (en) 2010-12-14 2020-01-15 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
EP2651437B1 (en) 2016-02-10
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
HRP20191843T1 (hr) 2019-12-27
DK2651437T3 (en) 2016-05-02
ES2748651T3 (es) 2020-03-17
EP2651436A1 (en) 2013-10-23
PT2651436E (pt) 2016-06-08
EP2651437A1 (en) 2013-10-23
JP5951634B2 (ja) 2016-07-13
HUE028452T2 (en) 2016-12-28
PT3023106T (pt) 2019-11-04
SI2651437T1 (sl) 2016-05-31
WO2012080370A1 (en) 2012-06-21
SMT201600118B (it) 2016-07-01
US20160220656A1 (en) 2016-08-04
KR20190022897A (ko) 2019-03-06
EA201390631A1 (ru) 2014-11-28
CN103260642B (zh) 2018-03-16
US9352030B2 (en) 2016-05-31
JP5951633B2 (ja) 2016-07-13
MX2013006819A (es) 2013-08-26
IL226450A0 (en) 2013-07-31
MX344280B (es) 2016-12-09
RS54687B1 (en) 2016-08-31
DK3023106T3 (da) 2019-09-30
EA027504B1 (ru) 2017-08-31
SI3023106T1 (sl) 2019-11-29
CN106822883A (zh) 2017-06-13
CO6751287A2 (es) 2013-09-16
EP3023106B1 (en) 2019-07-31
UA110118C2 (uk) 2015-11-25
CN103249431A (zh) 2013-08-14
SG190937A1 (en) 2013-07-31
CO6751288A2 (es) 2013-09-16
MX2013006818A (es) 2013-08-26
IL226448A (en) 2017-09-28
ZA201304015B (en) 2018-12-19
BR112013014599A2 (pt) 2016-09-27
EA027920B1 (ru) 2017-09-29
BR112013014598A2 (pt) 2017-09-19
EA201390630A1 (ru) 2013-12-30
CA2819297A1 (en) 2012-06-21
HUE027932T2 (en) 2016-11-28
AU2011343367B2 (en) 2015-05-21
CN103249431B (zh) 2016-11-02
KR20130124525A (ko) 2013-11-14
PL3023106T3 (pl) 2019-12-31
CN103260642A (zh) 2013-08-21
MX344706B (es) 2017-01-03
US9730992B2 (en) 2017-08-15
LT3023106T (lt) 2019-10-25
EP2651436B1 (en) 2016-03-30
JP2013545783A (ja) 2013-12-26
AU2011343367A1 (en) 2013-07-11
AU2011343368A1 (en) 2013-07-11
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
WO2012080369A1 (en) 2012-06-21
DK2651436T3 (da) 2016-06-20
ES2567190T3 (es) 2016-04-20
UY33802A (es) 2012-07-31
AU2011343368C1 (en) 2015-12-24
PL2651437T3 (pl) 2016-07-29
AU2011343368B2 (en) 2015-08-20
SG190731A1 (en) 2013-07-31
US20130280289A1 (en) 2013-10-24
EP3023106A1 (en) 2016-05-25
JP2014505036A (ja) 2014-02-27
IL226448A0 (en) 2013-07-31
CA2819298A1 (en) 2012-06-21
HRP20160606T1 (hr) 2016-07-01
US20130287809A1 (en) 2013-10-31
ZA201304014B (en) 2017-04-26
MY161412A (en) 2017-04-14
KR101951894B1 (ko) 2019-02-26
PL2651436T3 (pl) 2016-10-31
KR20140029376A (ko) 2014-03-10
ES2574403T3 (es) 2016-06-17
EP3593813A1 (en) 2020-01-15
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
SI2651436T1 (sl) 2016-07-29
US20180071378A1 (en) 2018-03-15
TW201305192A (zh) 2013-02-01
CY1122187T1 (el) 2020-11-25
US20190183998A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
UA110806C2 (uk) Мікобактеріальна антигенна композиція
MX350541B (es) Materiales y metodos para mejorar la funcion gastrointestinal.
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
MY162146A (en) Pharmaceutical composition
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
GB201106750D0 (en) Novel compounds
MX343870B (es) Compuestos que contienen mesógeno.
GB201106743D0 (en) Novel compounds
IN2015DN02729A (uk)
AU337185S (en) Oral care implement
MX358716B (es) Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas.
AU337044S (en) Oral care implement
MY161601A (en) Films and compositions comprising the same
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
BR112015020079A2 (pt) composições para cuidado oral
MX2012007970A (es) Proceso para la preparacion de una biomasa que comprende plantaricina y usos de la misma en el campo medico.
AU343717S (en) Sticking plaster used for medical purposes
AU337319S (en) Oral care implement
BR112014013327A2 (pt) composições para cuidado oral
AU337592S (en) Oral care implement
AU343718S (en) Sticking plaster used for medical purposes
CY1117640T1 (el) Αντιγονικη συνθεση μυκοβακτηριου